Cellectis, the French genome engineering specialist, has granted Boehringer Ingelheim a license on the European Patents N°EP 182 6215, EP 682 111, EP 682 112 and EP 419 621 to obtain, breed and utilize animal models in pharmaceutical research throughout Europe. This license covers an Institut Pasteur technology for introducing new features in genomes, for which Cellectis has an exclusive license. The terms of the contract have not been disclosed.

“The technologies developed at the Institut Pasteur have provided the pharmaceutical industry, among others, with highly efficient tools that have a wide variety of applications, in research as well as in drug development, and for many different diseases. We’re proud that Boehringer Ingelheim recognizes the value of such technologies,” said Cellectis’ CEO André Choulika. “We will continue to pursue appropriate recognition of these patents within the healthcare industry and seek to receive the proper value for our own patents in the same way, to fund our research programs.”